Efficacy and Safety of Nonantibiotic Outpatient Treatment in Mild Acute Diverticulitis (DINAMO-study) A Multicentre, Randomised, Open-label, Noninferiority Trial

被引:36
|
作者
Mora-Lopez, Laura [1 ]
Ruiz-Edo, Neus [1 ]
Estrada-Ferrer, Oscar [2 ]
Luisa Pinana-Campon, Maria [3 ]
Labro-Ciurans, Meritxell [4 ]
Escuder-Perez, Jordi [5 ]
Sales-Mallafre, Ricard [6 ]
Rebasa-Cladera, Pere [1 ]
Navarro-Soto, Salvador [1 ]
Serra-Aracil, Xavier [1 ]
机构
[1] Univ Autonoma Barcelona, Coloproctol Unit, Parc Tauli Univ Hosp,Dept Surg, Sabadell,Inst Invest & Innovacio,Parc Tauli I3PT, Barcelona, Spain
[2] Mataro Hosp, Coloproctol Unit, Mataro, Spain
[3] Hosp Univ St Joan Reus, Dept Surg, Reus, Spain
[4] Hosp St Joan de Deu Manresa, Dept Surg, Manresa, Spain
[5] Joan XXIII Univ Hosp, Coloproctol Unit, Tarragona, Spain
[6] Hosp St Pau & Santa Tecla, Santa Tecla, El Salvador
关键词
mild acute diverticulitis; nonantibiotic in acute diverticulitis; outpatient in acute diverticulitis; MODIFIED NEFF CLASSIFICATION; CLINICAL-TRIAL; ANTIBIOTICS; MANAGEMENT;
D O I
10.1097/SLA.0000000000005031
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective: Mild AD can be treated safely and effectively on an outpatient basis without antibiotics. Summary of Background Data: In recent years, it has shown no benefit of antibiotics in the treatment of uncomplicated AD in hospitalized patients. Also, outpatient treatment of uncomplicated AD has been shown to be safe and effective. Methods: A Prospective, multicentre, open-label, noninferiority, randomized controlled trial, in 15 hospitals of patients consulting the emergency department with symptoms compatible with AD. The Participants were patients with mild AD diagnosed by Computed Tomography meeting the inclusion criteria were randomly assigned to control arm (ATB-Group): classical treatment (875/125 mg/8 h amoxicillin/clavulanic acid apart from anti-inflammatory and symptomatic treatment) or experimental arm (Non-ATB-Group): experimental treatment (antiinflammatory and symptomatic treatment). Clinical controls were performed at 2, 7, 30, and 90 days. The primary endpoint was hospital admission. Secondary endpoints included number of emergency department revisits, pain control and emergency surgery in the different arms. Results: Four hundred and eighty patients meeting the inclusion criteria were randomly assigned to Non-ATB-Group (n = 242) or ATB-Group (n = 238). Hospitalization rates were: ATB-Group 14/238 (5.8%) and Non-ATB-Group 8/242 (3.3%) [mean difference 2.58%, 95% confidence interval (CI) 6.32 to -1.17], confirming noninferiority margin. Revisits: ATB-Group 16/238 (6.7%) and Non-ATB-Group 17/242 (7%) (mean difference -0.3, 95% CI 4.22 to -4.83). Poor pain control at 2 days follow up: ATB-Group 13/230 (5.7%), Non-ATB-Group 5/221 (2.3%) (mean difference 3.39, 95% CI 6.96 to -0.18). Conclusions: Nonantibiotic outpatient treatment of mild AD is safe and effective and is not inferior to current standard treatment.
引用
收藏
页码:E435 / E442
页数:8
相关论文
共 50 条
  • [1] Safety of Daiobotampito in the Treatment of Acute Diverticulitis of the Colon: A Single-Center, Open-Label, Prospective Trial
    Koike, Hiroshi
    Nakazawa, Atsushi
    Horiba, Yuko
    Tsukada, Nobuhiro
    Watanabe, Kenji
    JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE, 2017, 23 (11) : 885 - 889
  • [2] A multicentre open-label safety and efficacy study of tetrodotoxin for cancer pain
    Hagen, N. A.
    Lapointe, B.
    Ong-Lam, M.
    Dubuc, B.
    Walde, D.
    Gagnon, B.
    Love, R.
    Goel, R.
    Hawley, P.
    Ngoc, A. Ho
    du Souich, P.
    CURRENT ONCOLOGY, 2011, 18 (03) : E109 - E116
  • [3] Safety and efficacy of immunoguided prophylaxis for cytomegalovirus disease in low-risk lung transplant recipients in Spain: a multicentre, open-label, randomised, phase 3 noninferiority trial
    Paez-Vega, Aurora
    Vaquero-Barrios, Jose M.
    Ruiz-Arabi, Elisa
    Iturbe-Fernandez, David
    Alonso, Rodrigo
    Ussetti-Gil, Piedad
    Monforte, Victor
    Pastor, Amparo
    Fernandez-Moreno, Raquel
    Mora, Victor M.
    Erro-Iribarren, Marta
    Quezada, Carlos A.
    Berastegui, Cristina
    Cifrian-Martinez, Jose M.
    Cano, Angela
    Caston, Juan J.
    Machuca, Isabel
    Lobo-Acosta, Maria A.
    Gutierrez-Gutierrez, Belen
    Cantisan, Sara
    Torre-Cisneros, Julian
    LANCET REGIONAL HEALTH-EUROPE, 2025, 52
  • [4] Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial
    Abu Dayyeh, Barham K.
    Maselli, Daniel B.
    Rapaka, Babusai
    Lavin, Thomas
    Noar, Mark
    Hussan, Hisham
    Chapman, Christopher G.
    Popov, Violeta
    Jirapinyo, Pichamol
    Acosta, Andres
    Vargas, Eric J.
    Storm, Andrew C.
    Bazerbachi, Fateh
    Ryou, Marvin
    French, Matthew
    Noria, Sabrena
    Molina, Daniel
    Thompson, Christopher C.
    LANCET, 2021, 398 (10315): : 1965 - 1973
  • [5] External Trigeminal Nerve Stimulation for the Acute Treatment of Migraine: Open-Label Trial on Safety and Efficacy
    Chou, Denise E.
    Gross, Giti J.
    Casadei, Camilla H.
    Yugrakh, Marianna Shnayderman
    NEUROMODULATION, 2017, 20 (07): : 678 - 683
  • [6] Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial
    O'Callaghan, FinbarJ K.
    Edwards, Stuart W.
    Alber, Fabienne Dietrich
    Hancock, Eleanor
    LJohnson, Anthony
    Kennedy, Colin R.
    Likeman, Marcus
    Lux, Andrew L.
    Mackay, Mark
    Mallick, Andrew A.
    Newton, Richard W.
    Nolan, Melinda
    Pressler, Ronit
    Rating, Dietz
    Schmitt, Bernhard
    Verity, Christopher M.
    Osborne, John P.
    LANCET NEUROLOGY, 2017, 16 (01): : 33 - 42
  • [7] Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters: An open-label extension trial
    Wheless, James W.
    Meng, Tze-Chiang
    Van Ess, Peter J.
    Detyniecki, Kamil
    Sequeira, David J.
    Pullman, William E.
    EPILEPSIA, 2019, 60 (09) : 1809 - 1819
  • [8] Antiplatelet Therapy in Acute Mild-Moderate Ischemic Stroke (ATAMIS): a parallel, randomised, open-label, multicentre, prospective study
    Hou, Xiaowen
    Li, Xiaoqiu
    Wang, Xinhong
    Chen, Huisheng
    STROKE AND VASCULAR NEUROLOGY, 2018, 3 (04) : 263 - 267
  • [9] An Open-Label Trial of Aripiprazole Treatment in Dual Diagnosis Individuals: Safety and Efficacy
    McRae-Clark, Aimee L.
    Verduin, Marcia L.
    Tolliver, Bryan K.
    Carter, Rickey E.
    Wahlquist, Amy E.
    Brady, Kathleen T.
    Cluver, Jeffrey S.
    Anderson, Samantha
    JOURNAL OF DUAL DIAGNOSIS, 2009, 5 (01) : 83 - 96
  • [10] Endovascular thrombectomy for acute ischaemic stroke with established large infarct: multicentre, open-label, randomised trial
    Bendszus, Martin
    Fiehler, Jens
    Subtil, Fabien
    Bonekamp, Susanne
    Aamodt, Anne Hege
    Fuentes, Blanca
    Gizewski, Elke R.
    Hill, Michael D.
    Krajina, Antonin
    Pierot, Laurent
    Simonsen, Claus Z.
    Zelenak, Kamil
    Blauenfeldt, Rolf A.
    Cheng, Bastian
    Denis, Angelique
    Deutschmann, Hannes
    Dorn, Franziska
    Flottmann, Fabian
    Gellissen, Susanne
    Gerber, Johannes C.
    Goyal, Mayank
    Haring, Jozef
    Herweh, Christian
    Hopf-Jensen, Silke
    Hua, Vi Tuan
    Jensen, Maerit
    Kastrup, Andreas
    Keil, Christiane Fee
    Klepanec, Andrej
    Kurca, Egon
    Mikkelsen, Ronni
    Moehlenbruch, Markus
    Mueller-Huelsbeck, Stefan
    Muennich, Nico
    Pagano, Paolo
    Papanagiotou, Panagiotis
    Petzold, Gabor C.
    Pham, Mirko
    Puetz, Volker
    Raupach, Jan
    Reimann, Gernot
    Ringleb, Peter Arthur
    Schell, Maximilian
    Schlemm, Eckhard
    Schoenenberger, Silvia
    Tennoe, Bjorn
    Ulfert, Christian
    Valis, Katerina
    Vitkova, Eva
    Vollherbst, Dominik F.
    LANCET, 2023, 402 (10414): : 1753 - 1763